The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback